Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy.
COVID-19
Immunogenicity
Lung cancer
Radiotherapy
SARS-CoV-2
mRNA vaccine
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
23
08
2021
revised:
14
11
2021
accepted:
15
11
2021
pubmed:
29
11
2021
medline:
25
2
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
The immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy is unknown. This prospective cohort study demonstrates that anti-SARS-CoV-2 spike antibody and neutralization titers are reduced in a subset of thoracic radiotherapy patients, possibly due to immunosuppressive conditions. Antibody testing may be useful to identify candidates for additional vaccine doses.
Identifiants
pubmed: 34838892
pii: S0167-8140(21)09005-8
doi: 10.1016/j.radonc.2021.11.012
pmc: PMC8613981
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
88-91Subventions
Organisme : NIDA NIH HHS
ID : DP2 DA040254
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Gainor has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, Moderna, AstraZeneca, Pfizer, Novartis, Merck, and GlydeBio; research support from Novartis, Genentech/Roche, and Ariad/Takeda; institutional research support from Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an employee with equity at Ironwood Pharmaceuticals. None of the other authors has declared a competing interest.
Références
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
Nephrol Dial Transplant. 2021 Aug 27;36(9):1704-1709
pubmed: 34057463
Cancer Cell. 2020 Nov 9;38(5):629-646
pubmed: 33049215
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
JTO Clin Res Rep. 2021 Jan;2(1):100124
pubmed: 33205053
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Radiother Oncol. 2021 Apr;157:225-233
pubmed: 33577865
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
J Clin Oncol. 2022 Jan 1;40(1):12-23
pubmed: 34752147